Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: A randomized, double-blind, placebo-controlled trial

International Journal of Neuropsychopharmacology

Volumn 13, Issue 8, 2010, Pages 1115-1125

  Fleischhacker, W Wolfgang ^a   Heikkinen, Martti E ^b   Olié, Jean Pierre ^c   Landsberg, Wally ^d   Dewaele, Patricia ^d   McQuade, Robert D ^e   Loze, Jean Yves ^f   Hennicken, Delphine ^d   Kerselaers, Wendy ^d  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b Helsinki City Health Centre   (Finland)

^c CENTRE HOSPITALIER SAINTE ANNE   (France)

^d BRISTOL MYERS SQUIBB   (United States)

^e OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

^f Otsuka Pharmaceuticals France   (France)

Author keywords

Adjunctive; aripiprazole; clozapine; schizophrenia

Indexed keywords

ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; ARIPIPRAZOLE; CHOLESTEROL; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TRIACYLGLYCEROL;

ADULT; AKATHISIA; ANXIETY DISORDER; ARTICLE; BODY MASS; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GLUCOSE BLOOD LEVEL; HEADACHE; HUMAN; INSOMNIA; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; OPEN STUDY; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SCHIZOPHRENIA; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; VOMITING; WAIST CIRCUMFERENCE; WEIGHT GAIN; WEIGHT REDUCTION;

ADOLESCENT; ADULT; AGED; BODY MASS INDEX; BODY WEIGHT; CHEMOTHERAPY, ADJUVANT; CHOLESTEROL; CLOZAPINE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; QUINOLONES; SCHIZOPHRENIA; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77957230409     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145710000490     Document Type: Article

References (31)

1. Allison DB, Mackell JA, McDonnell DD (2003). The impact of weight gain on quality of life among persons with schizophrenia. Psychiatric Services 54, 565-567. (Pubitemid 36752990)
2. American Diabetes Association, APA (2004). Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 27, 596-601.
3. APA (2000). Diagnostic and Statistical Manual of Mental Disorders, 4th edn, text revision. Washington, DC: American Psychiatric Association.
4. Brixner DL, Said Q, Corey-Lisle PK, Tuomari AV, et al. (2006). Naturalistic impact of second-generation antipsychotics on weight gain. Annals of Pharmacotherapy 40, 626-632
5. Burris KD, Molski TF, Xu C, Ryan E, et al. (2002). Aripiprazole, a novel antipsychotic, is a high-affinity, partial agonist at human dopamine D2 receptors. Journal of Pharmacology and Experimental Therapeutics 302, 381-389. (Pubitemid 34680462)
6. Chang JS, Ahn YM, Park HJ, Lee KY, et al. (2008). Aripiprazole augmentation in clozapine-treated patients with refractory schizophrenia: an 8-week, randomized, double-blind, placebo-controlled trial. Journal of Clinical Psychiatry 69, 720-731. (Pubitemid 351838681)
7. Englisch S, Zink M (2008). Combined antipsychotic treatment involving clozapine and aripiprazole. Progress in Neuropsychopharmacology and Biological Psychiatry 32, 1386-1392. (Pubitemid 352033663)
8. Fleischhacker WW (1999). Clozapine: a comparison with other novel antipsychotics. Journal of Clinical Psychiatry 60, 30-34. (Pubitemid 29283180)
9. Fleischhacker WW (2005). Aripiprazole. Expert Opinion in Pharmacotherapy 6, 2091-2101.
10. Fleischhacker WW, McQuade RD, Marcus RN, Archibald D, et al. (2009). A double-blind, randomized comparative study of aripiprazole and olanzapine in patients with schizophrenia. Biological Psychiatry 65, 510-517.
11. Fleischhacker WW, Cetkovich-Bakmas M, De Hert M, Hennekens CH, et al. (2008). Comorbid somatic illnesses in patients with severe mental disorders: clinical, policy, and research challenges. Journal of Clinical Psychiatry 69, 514-519. (Pubitemid 351792324)
12. Guy W (ed). (1976). ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: US Department of Heath, Education, and Welfare Public Health Service Alcohol, Drug Abuse, and Mental Health Administration.
13. Hann DM, Jacobsen PB, Azzarello LM, Martin SC, et al. (1998). Measurement of fatigue in cancer patients: development and validation of the fatigue symptom inventory. Quality of Life Research 7, 301-310.
14. Henderson DC, Kunkel L, Nguyen DD, Borba CP, et al. (2006). An exploratory open-label trial of aripiprazole as an adjuvant to clozapine therapy in chronic schizophrenia. Acta Psychiatrica Scandinavica 113,142-147. (Pubitemid 43340908)
15. Johns MW (1991). A new method for measuring daytime sleepiness: the Epworth Sleepiness Scale. Sleep 14,540-545.
16. Jordan S, Koprivica V, Chen R, Tottori K, et al. (2002). The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. European Journal of Pharmacology 441, 137-140. (Pubitemid 34626163)
17. Kahn RS, Fleischhacker WW, Boter H, Davidson M, et al. for the EUFEST Study Group (2008). Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 371, 1085-1097. (Pubitemid 351418005)
18. Kane JM, Leucht S, Carpenter D, Docherty JP (2003). Expert consensus panel for optimizing pharmacologic treatment of psychotic disorders. The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. introduction: methods, commentary, and summary. Journal of Clinical Psychiatry 64, 5-19.
19. Kay SR, Fiszbein A, Opler LA (1987). The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin 13, 261-276. (Pubitemid 18039085)
20. Keck Jr. PE, McElroy SL (2003). Aripiprazole: a partial dopamine D2 receptor agonist antipsychotic. Expert Opinion on Investigational Drugs 12, 655-662. (Pubitemid 36512009)
21. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, et al. (2005). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine 353, 1209-1223. (Pubitemid 41345943)
22. Naber D (1995). A self-rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life, compliance and other clinical variables. International Clinical Psychopharmacology 10, 133-138. (Pubitemid 26054887)
23. Newcomer JW (2005). Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs19, 1-93. (Pubitemid 40677047)
24. Newcomer JW, Campos JA, Marcus RN, Breder C, et al. (2008). A multicenter, randomised, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine. Journal of Clinical Psychiatry 69,1046-1056. (Pubitemid 352031586)
25. Sanjuan J, Prieto L, Olivares JM, Ros S, et al. (2003). GEOPTE scale of social cognition for psychosis. Actas Espanolas de Psiquiatria 31, 120-128. (Pubitemid 36959598)
26. Shapiro DA, Renock S, Arrington E, Chiodo LA, et al. (2003). Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 28, 1400-1411. (Pubitemid 41070874)
27. Simpson GM, Angus JWS (1970). A rating scale for extrapyramidal side-effects. Acta Psychiatrica Scandinavica 212, 11-19.
28. Tandon R, Devellis RF, Han J, Li H, et al. (2005). Validation of the investigator's assessment questionnaire, a new clinical tool for relative assessment of response to antipsychotics in patients with schizophrenia and schizoaffective disorder. Psychiatry Research 136, 211-221. (Pubitemid 41765219)
29. Tschoner A, Engl J, Laimer M, Kaser S, et al. (2007). Metabolic side effects of antipsychotic medication. International Journal of Clinical Practice 61, 1356-1370. (Pubitemid 47052363)
30. Weiden PJ, Mackell J, McDonnell DD. (2000). Obesity as a risk factor for antipsychotic non-compliance. Presented at the Annual New Clinical Drug Evaluation Unit (NCDEU) Conference, Boca Raton, FL.
31. Wilson PW, D'Agostino RB, Levy D, Belanger AM, et al. (1998). Prediction of coronary heart disease using risk factor categories. Circulation 97,1837-1847. (Pubitemid 28213628)